🌍·1d agoIndustry
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Publisher
A
Allogene Therapeutics
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on allogene.com
Leave the platform to read the original full article on the publisher site.
Source: Allogene Therapeutics
Scope: Industry
Related coverage
More related coverage
WuXi Biologics·14h ago
Quality Director of Operations
WuXi Biologics·14h ago
Director, Scientific Advisor, Antibody Discovery
WuXi Biologics·14h ago
Director, Scientific Advisor, In Vivo Pharmacology
Zymeworks·20h ago